Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis (Q21146683)

Dimensions

17 August 2022

Igho J Onakpoya

1

Igho J

Onakpoya

1 reference

Dimensions

1023060105

17 August 2022

Carl J Heneghan

series ordinal

2

author given names

Carl J

author last names

Heneghan

1 reference

Dimensions

1023060105

Creative Commons Attribution 4.0 International

17 August 2022

language of work or name

English

0 references

publication date

2015

0 references

published in

BMC Medicine

0 references

volume

13

0 references

page(s)

26

0 references

issue

1

0 references

copyright license

start time

5 February 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s12916-014-0262-7

0 references

cites work

Anecdotes that provide definitive evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

India's health ministry bans pioglitazone, metamizole, and flupentixol-melitracen

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Systematic reviews of adverse effects: framework for a structured approach

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Global health philanthropy and institutional relationships: how should conflicts of interest be addressed?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Development and delivery of clinical pharmacology in regulatory agencies

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

A strategy for regulatory action when new adverse effects of a licensed product emerge.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Methods for causality assessment of adverse drug reactions: a systematic review

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Case reports of suspected adverse drug reactions--systematic literature survey of follow-up

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

The role of data mining in pharmacovigilance

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Adverse drug reactions: keeping up to date

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

The CARE guidelines: consensus-based clinical case reporting guideline development.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Lessons from the withdrawal of rofecoxib

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Hazardous drugs in developing countries

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Concepts in risk-benefit assessment. A simple merit analysis of a medicine?

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

Sudden death in an infant from methemoglobinemia after administration of "sweet spirits of nitre"

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4318389

An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0262-7

Suicide by injection of a veterinarian barbiturate euthanasia agent: report of a case and toxicological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0262-7

Pumactant and poractant alfa in respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0262-7

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0262-7

EMA consults public on plan to increase transparency of drug trial data

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

AN INTERNATIONAL DRUG SAFETY PROGRAM

1 reference

12 December 2020

Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study

1 reference

12 December 2020

Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety

1 reference

12 December 2020

A FATALITY ASSOCIATED WITH DITHIAZANINE IODIDE THERAPY

1 reference

12 December 2020

10.1186/S12916-014-0262-7

Identifiers

DOI

0 references